RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Long Hill Capital of Beijing and Shanghai, which is focused on investments in the healthcare and consumer sectors, has closed its second fund at $265 million. The firm’s first fund raised $125 million in 2016. Long Hill said the new fund “significantly exceeded” its original funding target, showing the success of its thesis-investing strategy. According to the firm, more than 80% of the investments so far have been in Series A rounds.
Source: China Biotoday
